Clinical Trial Watch: Localized Prostate Cancer
May 15th 2010This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase I and II localized prostate cancer trials that are currently recruiting participants. This list is current as of April 28, 2010.
Recurrent prostate cancer may be detected better wih new diagnostics
May 15th 2010Targets for improving the state of management of advanced prostate cancer include the development of new diagnostic modalities with better performance in detecting recurrent disease, additional monotherapy or combination treatment options, and strategies for mitigating the risks of androgen deprivation therapy.
Urodynamic studies are on the rise
May 15th 2010The number of urodynamic studies conducted by urologists applying for board certification or recertification more than doubled in less than a decade, with most of the procedures being performed in men with symptoms of urinary obstruction and in women with urinary incontinence.
Medicare contractor in Southeast retires least costly alternative LCD
May 13th 2010Pinnacle Business Solutions Inc. Medicare Services has announced the retirement of least costly alternative (LCA) local coverage determinations (LCDs) for certain prostate cancer drugs, a move AUA called a "welcome development."
Biomarkers may predict men needing PCa treatment
May 13th 2010A blood test for certain forms of PSA and measurement of DNA content in biopsy tissue accurately predict which men with potentially non-lethal prostate cancers may eventually need treatment, say urologists from Johns Hopkins University, Baltimore.
FDA: GnRH agonists associated with small risk of diabetes, death
May 13th 2010Gonadotropin-releasing hormone (GnRH) agonists have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several FDA studies.